CVR 36899069Public limited company (A/S)Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)Aarhus NFounded 7 May 2015
Employees
64
CVR registry, Aug 2026
+11 (+20.8%) over 12 months
Gross profit
-26.1M
EUR, annual report 2025
Result
-33M
EUR, annual report 2025
Equity
12.4M
EUR, annual report 2025
Compiled by Dandex from the Central Business Register (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish company data. Connect it once and ask about NMD Pharma A/S, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set Up DandexJeito S.L.P.33.3% to under 50% of capital and votes, since 4 Feb 2022
LUNDBECKFOND INVEST A/SCVR 21855545, 15% to under 20% of capital and votes, since 2 Jun 2016
and 3 moreThomas Holm Pedersensince 7 May 2015
CVR 2185554515% to under 20% of capital and votessince 2 Jun 2016
CVR 2425763015% to under 20% of capital and votessince 2 Jun 2016
10% to under 15% of capital and votessince 5 Mar 2018
33.3% to under 50% of capital and votessince 4 Feb 2022
15% to under 20% of capital and votessince 30 Jun 2026
Holders of 5% or more, from the owner register. CVR records shares in bands, not exact figures.
CVR 320825995% to under 10% of capital and votes21 May 2015 to 5 Mar 2018
CVR 199184405% to under 10% of capital and votes2 Jun 2016 to 5 Mar 2018
CVR 368987555% to under 10% of capital and votes21 May 2015 to 29 Mar 2019
CVR 3689879810% to under 15% of capital and votes21 May 2015 to 1 Jun 2016
15% to under 20% of capital and votes5 Mar 2018 to 30 Jun 2026
CVR records founders at incorporation. It does not record whether they are alive or still involved.
7 May 2015 to 1 Nov 2026.
2 Jun 2016 to 1 Nov 2026.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Gross profit | -11,029 | -9,480 | -19,182 | -27,874 | -26,063 |
| Operating profit | -14,253 | -12,980 | -23,241 | -33,853 | -34,083 |
| Result for the year | -13,614 | -12,324 | -22,401 | -32,254 | -32,985 |
| Equity | 2,596 | 25,133 | 42,673 | 35,395 | 12,410 |
| Total assets | 4,920 | 27,139 | 46,393 | 39,394 | 23,005 |
| Employees (average) | 26 | 26 | 31 | 36 | 49 |
| Credit metrics (Dandex calculations) | |||||
| EBITDA | Not reportednote 1 | -12,980note 2 | -23,222 | -33,817 | -34,029 |
| Employee growth (vækst i antal ansatte) | 18.2% | 0% | 19.2% | 16.1% | 25.6% |
| Net interest-bearing debt (NIBD, nettorentebærende gæld) | -3,801 | -25,789 | -45,042 | -38,070 | -21,309 |
| Capex (investeringer i anlægsaktiver) | Not reportednote 3 | 95note 4 | 85note 4 | 0note 4 | 150note 5 |
EUR thousands. Annual reports via XBRL. Employees are the annual report's average and may cover a group.
Credit metrics are Dandex calculations from the filed figures, not filed values; estimates are in grey with a note. Ratios are percentages and gearing a multiple. Definitions. Revenue-based rows are empty: the company reports gross profit only (bruttofortjeneste), which class B filers may. No cash flow statement filed (class A and B are exempt).
Annual report 2025
1 Jan 2025 to 31 Dec 2025, published 11 Jun 2026
Annual report 2024
1 Jan 2024 to 31 Dec 2024, published 30 Jun 2025
Annual report 2023
1 Jan 2023 to 31 Dec 2023, published 24 Jun 2024
Annual report 2022
1 Jan 2022 to 31 Dec 2022, published 4 Jul 2023
Annual report 2021
1 Jan 2021 to 31 Dec 2021, published 15 Jun 2022
NMD Pharma A/S has changed ownership. A new strategy and new needs can be expected.
Signal, a Dandex estimate. Lapses 13 Nov 2026.
2 registered in CVR.
P-number 1020416218Palle Juul-Jensens Boulevard 82, 8200 Aarhus N
P-number 1029145233Fruebjergvej 3, 2100 København Ø
No other current company drawn.
No other current company drawn.
No other current company drawn.
No other current company drawn.
No other current company drawn.
